General Overview to the CTD and Module 1

Slides:



Advertisements
Similar presentations
1 Harmonisation of requirements: where we are Erik Waterdrinker, IFAH-Europe 2nd Veterinary Workshop on E-submission 4 Dec 2009, EMEA, London.
Advertisements

Registration in Europe Current situation and future outlook Thomas K ü rner, M.D. Nippon Boehringer Ingelheim Co., Ltd.
Dr. Raghuveer Pharma Consultants D R P C Quality. Perfection. Confidentiality. D R P C Quality. Perfection. Confidentiality. 1.
BROMI Variations Training Meeting 8th May 2008 Case Study Session BROMI VARIATIONS.
The European Agency for the Evaluation of Medicinal Products 1 FFUL LisbonHilde Boone - EMEA 29 May 2003 EU Variation Regulations (541/95 and 542/95) Final.
GMP Document and Record Retention
IMP/Placebo Sourcing, Release, Storage and Reconciliation. Ms Caroline Whiriskey Research Pharmacist, HRB Clinical Research Facility Galway.
Batch Reworking and Reprocessing
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Active Pharmaceutical Ingredient Master.
©2014 Factorytalk Co., Ltd. Proprietary and Confidential eCTD Specification 17 July 2014.
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Variations Maintenance of Prequalified.
Variations to Prequalified Medicines Rutendo Kuwana Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Lynda Paleshnuik | January |1 | Assessment Workshop Copenhagen – January 2011 QIS/QOS: The new PQP quality templates.
Management of Change Control. Overview Changes – Good or bad? Forced or voluntary? The Importance of Change Control Major Changes to both legacy company.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Structure of Dossier of Medicinal Product- Q part
Post approval changes- Variations Mercy Acquaye. Presentation Outline Introduction to Guidance Classification of changes Approval of changes Definitions.
Registration in lebanon
EFPIA EFPIA IT Proposals ppt Slide 1 EFPIA Proposals for IT Support to the European Regulatory Procedures Mr S. Hasler EFPIA PAT Regulation 2000.
Justina A. Molzon, MS Pharm, JD
Christa Clasen Ankara, 6./7. April 2006
Quality of Substances for Pharmaceutical Use: The EDQM Certification of Suitability to the European Pharmacopoeia Monographs (CEP) Dr. Susanne Keitel DIA.
Authorisation of medicinal products: selected challenges Rocío Salvador Roldán Pharmaceuticals Unit/DG SANCO This presentation only reflects the views.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Monograph Development Process for the European Pharmacopoeia: How to participate in the work programme of the European Pharmacopoeia Dr Claude Coune Head.
DEPARTMENT OF HEALTH Medicines Regulatory Affairs
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
An agency of the European Union Presented by: Emer Cooke and Truus Janse-de Hoog Update on Transparency Progress report from HMA/EMA TF on Transparency.
Paediatric Worksharing CMDh participation Work-sharing in Art 45 and 46 procedures Experiences in Art 29 procedures Presidency meeting 29 September 2011.
Theo Dekker -- CPH -- Nov |2 | Meeting of WHO PQP with European manufacturers and EU holders of marketing authorisations WHO Prequalification of.
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
Federal agency for medicines and health products EC REGULATION 1901/2006 ON MEDICINAL PRODUCTS FOR PAEDIATRIC USE AND HOMEOPATHIC MEDICINAL PRODUCTS Marie-Anne.
HELM AG Module 3 Christa Clasen Ankara, 6./7. April 2006.
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
Lynda Paleshnuik | January |1 | Assessment Workshop Copenhagen – January 2011 The new PQP quality guideline.
CTD Dossier Preparation K. Srikantha Reddy Sr
FDA ICH Public Meeting 5630 Fishers Lane, Rockville, MD May 8, :30 am -- 2:00 pm Implementation of the CTD Update-Issues-Next Steps Justina A. Molzon,
International conference Quality of Active Pharmaceutical Ingredients Hyderabad, September 2009 API Inspections: the EDQM experience – 7 September.
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
European Patients’ Academy on Therapeutic Innovation Marketing authorisation.
Transatlantic Administrative Simplification Workshop European Preparatory Roundtable Suzette Kox EGA Senior Director Scientific Affairs.
The assessment process in “stringent” authorities Regine Lehnert Training workshop: Regulatory requirements for registration of Artemisinin based combined.
1 COMMON TECHNICAL DOCUMENT / ORIGIN OF CTD… ICH EWG CTD WAS OFFICIALLY SIGNED OFF IN NOVEMBER 2000, AT 5 TH ICH CONFERENCE; SAN DIEGO,CALIFORNIA.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
Chanchal C Sarkar DY. Director, Trade Policy Division Department of Commerce, Ministry of Commerce & Industry TBT Agreement : Key Principles.
THE OFFICE FOR REGISTRATION OF MEDICINAL PRODUCTS, MEDICAL DEVICES AND BIOCIDAL PRODUCTS Registration of medicinal products in European.
China EU Pharmaceutical Forum
DMF Procedures and Communication between API, FFP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
REGULATION (EC) Nº 1223/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 30 November 2009 on cosmetic products 1 Shall apply from 11.
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
An agency of the European Union Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 0070 Principles Industry.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
Dr Pascale POUKENS-RENWART Scientific Officer
Periodic Safety Update Reports (PSUR)
Information on Medicinal Products
LITERATURE REVIEW As the pharmaceutical industries throughout the world are moving ahead towards becoming more and more competitive, regulatory agencies.
CTD Content Management
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Handling ongoing variations concerning same document
Good Practices (GMP, GLP, GCP), inspections including Pharmacopoeias
GMP Inspection Process
EU SUBMISSION BY Haripriya & Revathy.
TBT Agreement : Key Principles
Recommendations to facilitate assessment of new application procedures
Variations and Mock-ups
Presentation transcript:

General Overview to the CTD and Module 1 Gudrun Dora Gisladottir Director Regulatory Affairs

Using CTD format Actavis group hf International generic pharmaceutical company First EU submissions in early ’90’s Captopril first MRP 1994 Finalize 10 – 20 new development projects per year CTD format in EU since 2002 First eCTD submitted

Using CTD format Already reformatted most of the “older” dossiers New markets Variations Renewals Mixed format >70 dossiers in CTD format

Common Technical Document (CTD) is; CTD Format What is it? Common Technical Document (CTD) is; A common format for presentation of technical documentation according to agreed international standards Built around ICH and a mixture of FDA/EU/Japanese standards It is not; A single file that will meet the needs of authorities – regional requirements and guidelines still apply where not covered by ICH

CTD Format Why use it? It is a regulatory requirement in EU! Logical order, representing sequential development path. User friendly review Theoretically possible to create “global dossier”! Queries and deficiency letters simpler to answer Agreement on defined terms assists the harmonization process between regions Electronic submission should be easier to prepare Encourages implementation of ICH guidelines

CTD – Is it worth it? From the Industry’s perspective; YES! For new submissions For dossiers already compiled in the NtA format, probably NO! Mixed format Variations Authorities ?

CTD outline of structure The CTD is organized into five modules Administrative, regional or national information is provided in Module 1 – content specified by individual authorities EU application form, the proposed SmPC, the labelling and package leaflet Modules 2, 3, 4 and 5 are intended to be common for all regions

CTD outline of structure Chemical, Pharmaceutical and Biological documentation is provided in the Quality Overall Summary from Module 2 and by Module 3 (previously Part II) Toxicological and Pharmaceutical Documentation is provided in the Non-clinical Written Summary from Module 2 and by the Non-clinical Study Reports in Module 4 (part III) The clinical documentation is provided in the Clinical Written Summary form Module 2 and in the Clinical Study Reports Module 5 (part IV)

CTD Module 2 Generic applications Module 2 contains high level summaries Quality Overall Summary, QOS (Module 2.3) Non clinical Overview / Summary, NCOS (Module 2.4) Clinical Overview / Summary COS (Module 2.5)

CTD Module 2 EU legal requirement that dossiers should be prepared by suitably qualified and experienced experts Though CTD format does not mention expert reports the content is expected to be given in the QOS, NCOS, COS Experts have to sign and give their CV

CTD Module 3 Replaces Part II Splits Drug Substance from Drug Product See correlation table for full details Splits Drug Substance from Drug Product S (DMF) and P Follows logic of Development process

Module 3 Drug Master File (DMF) What is a DMF? DMF is divided into two parts – the applicants part “open” and the drug substance manufacturers part “closed” part (confidential only to be reviewed by authorities) Applicant’s part provides sufficient information to allow evaluation of the suitability of the specification to control the quality Brief information on manufacturing Information on impurities arising from manufacturing method Information on degradation products Information on toxicity of impurities where applicable

Module 3 Drug Master File (DMF) Drug substance manufacturer gives permission to the authorities to access data in closed part as “Letter of Access” (LoA) Applicant submits the open part Use CTD format

Module 3 Drug Master File (DMF) 3.2.S.1 General Information 3.2.S.1.1 Nomenclature 3.2.S.1.2 Structure 3.2.S.1.3 General Properties 3.2.S.2 Manufacture 3.2.S.2.1 Manufacturer(s) 3.2.S.2.2 Description of Manufacturing Process and Process Controls 3.2.S.3 Control of Materials 3.2.S.3.1 Elucidation of Structure and Other Characteristics 3.2.S.3.2 Impurities 3.2.S.4 Control of Drug Substance 3.2.S.4.1 Specification 3.2.S.4.2 Analytical Procedure 3.2.S.4.3 Validation of Analytical Procedures 3.2.S.4.4 Batch Analyses 3.2.S.4.5 Justification of Specification 3.2.S.5 Reference standards or Materials 3.2.S.6 Container Closure System 3.2.S.7 Stability

Module 3 Certificate of Suitability Used for pharmacoepial substances (actives or excipients) Documentation submitted directly to Ph. Eur. Secretariat Avoid repeated assessment of same DMF by various authorities Certification scheme includes requirements for a declaration concerning GMP and willingness to be inspected Applicant includes the Certificate of Suitability (CoS) in the dossier

CTD Module 3 Drug Product 3.2.P.1 Description and Composition of the Drug Product 3.2.P.2 Pharmaceutical Development 3.2.P.2.4 Controls and Critical Steps 3.2.P.3 Manufacture 3.2.P.3.1 Manufacturer(s) 3.2.P.3.2 Batch Formula 3.2.P.3.3 Description of Manufacturing Process and Process Controls 3.2.P.3.4 Controls of Critical Steps and Intermediates 3.2.P.3.5 Process validation and/or evaluation

CTD Module 3 Drug Product 3.2.P.4 Control of excipients 3.2.P.4.5 Excipients of Human or Animal Origin 3.2.P.4.6 Novel Excipients 3.2.P.5 Control of Drug Product 3.2.P.5.1 Specification(s) 3.2.P.5.2 Analytical Procedures 3.2.P.5.3 Validation of Analytical Procedures 3.2.P.5.4 Batch Analyses 3.2.P.5.5 Characterisation of Impurities 3.2.P.5.6 Justification of Specification(s) 3.2.P.6 Reference Standards or Materials 3.2.P.7 Container Closure System 3.2.P.8 Stability

Module 4 For Generic Application Only literature review EU authorities – different opinion on whether this is needed in the application

Module 5 For a generic application Reports from literature BE report Justification and discussion regarding design and results 5.3.2 comparative BA and bioequivalence study

Common Technical Document Detailed Structure Fine details of requirements for each module: Revised Notice to Applicants Volume 2B published in June 2004 Sections in Part R; Regional information References are to ICH and CPMP guidelines Various Q and A documents available

CTD Presentations General Considerations Throughout the display of information should be unambiguous and transparent, to facilitate the review Use margins that allow the document to be printed on A4 paper The left hand margin should be sufficiently large that information is not obscured through binding Font sizes for text and tables should be of style and size that are large enough to be easily legible even after photocopying Acronyms and abbreviations should be defined the first time they are used in each module

CTD Presentation Organisation of sections ICH Guideline M4: CTD for the registration of Pharmaceuticals for human use; organisation of common technical document implemented 2003 – incorporates “Granularity Document” Defines how to split sections down into separate documents Prepares the way for electronic submission The Granularity guideline defines “Document” and states that each document should be paginated separately (electronic file)

CTD Presentation Organisation of sections Practical experience In deciding whether one or more documents or files are appropriate, it should be considered that once a particular approach has been adopted the same approach should be used throughout the life of the dossier since it is the intention that replacement documents/files be provided when information is changed

CTD Presentation Organisation of sections For Module 3 the situation can be very complicated For a drug product containing more than one drug substance the information requested for part “S” should be provided in its entirety for each drug substance More than one Drug Substance supplier More than one manufacturing site for the finished product

Electronic Dossiers eCTD CTD makes it possible to agree upon standard for an electronic submission XML backbone plus PDF files Are authorities ready?

Global Dossier Major Challenges Level of details (U.S.A) e.g. description of synthesis, in process controls, raw materials, container Compendial differences – not all monographs are harmonized (USP, Ph. Eur.) GMP issues Stability, US requires site specific data, 3 months v.s. 6 months Plus the BE study!

Regional Information - EU Module 1 Regional Information - EU

Table of Content Typical Module 1 - Actavis 1.1 Comprehensive Table of Contents 1.2 Application Form Annexed Documents 6.3 Proof of establishment of MA holder 6.4 Letter of authorisation for communication 6.5 Curriculum Vitae of the Qualified Person for Pharmacovigilance 6.6 Manufacturing Authorisation 6.7 Justification for more than one manufacturer responsible for batch release 6.8 Flow-chart indicating the different sites involved in the manufacturing process 6.10 Letter of Access to DMF 6.11 Copy of written confirmation of the AIM 6.15 Copy of Marketing Authorization(s) required under Directive 2001/83/EC Proof of first Authorisation of essential similar medical product in EU 6.22 Declaration from the Qualified Person of the manufacturing authorisation holder

Table of Content Typical Module 1 – Actavis cont. 1.3 Summary of Product Characteristics, Labelling and Package Leaflet. 1.3.1 SPC 1.3.2 Labelling 1.3.3 PIL 1.3.4 Readability Justification 1.4 Information about the Experts 1.5.2 Information for abridged applications

Module 1 The application form is to be used for an application for a marketing authorisation of a medicinal product for human use submitted to (a) the European Agency for the Evaluation of Medicinal Products under the centralised procedure or (b) a Member State (as well as Iceland, Lichtenstein and Norway) under either a national, mutual recognition procedure or decentralised procedure.

Application Form EU - Region 1. Type of application 1.1 This application concerns 1.2 Orphan medicinal product designation 1.3 Referring to Annex II of Regulations (EC) N° 1084/2003 or1085/2003[1] 2. Marketing authorisation application particulars 2.1 Name(s) and ATC code 2.2 Strength, pharmaceutical form, route of administration, container and pack sizes 2.3 Legal status 2.4 Marketing authorisation holder, Contact persons, Company 2.5 Manufacturers 2.6 Qualitative and quantitative composition

Application Form EU - Region 3. Scientific advice 4. Paediatric Development Programme 5. Other marketing authorisation applications Appended documents 6.1 Proof of payment 6.2 Informed consent letter of marketing authorisation holder of authorised medicinal product. 6.3 Proof of establishment of the applicant in the EEA. 6.4 Letter of authorisation for communication on behalf of the applicant/MAH 6.5 Curriculum Vitae of the Qualified Person for Pharmacovigilance 6.6 Manufacturing Authorisation required under Article 40 of Directive 2001/83/EC (or equivalent, outside of the EEA where MRA or other Community arrangements apply). A reference to EudraGMP will suffice when available. 6.7 Justification for more than one manufacturer responsible for batch release in the EEA

Application Form EU - Region 6.8 Flow-chart indicating all sites involved in the manufacturing process of the medicinal product or active substance (including sites involved in sampling and testing for batch release of products manufactured in third countries). Note: ALL manufacturing and control sites mentioned throughout the whole dossier MUST be consistent regarding their names, detailed addresses and activities. 6.9 Statement (or GMP Certificate issued by an EEA inspectorate, when available) from the competent authority which carried out the inspection of the manufacturing site(s) (not older than 3 years). References to EudraGMP will suffice when available. Where applicable a summary of other GMP inspections performed in the last 2 years 6.10 Letter(s) of access to Active Substance Master File(s) or copy of Ph. Eur. Certificate(s) of suitability 6.11 Copy of written confirmation from the manufacturer of the active substance to inform the applicant in case of modification of the manufacturing process or specifications according to Annex I of Directive 2001/83/EC. 6.12 Ph. Eur. Certificate(s) of suitability for TSE 6.13 Written consent(s) of the competent authorities regarding GMO release in the environment.

Application Form EU - Region 6.14 Scientific Advice given by CHMP 6.15 Copy of Marketing Authorization(s) required under Article 8(j)-(L) of Directive 2001/83/EC in the EEA and the equivalent in third countries on request (a photocopy of the pages which give the marketing authorization number, the date of authorisation and the page which has been signed by the authorizing competent authority will suffice). 6.16 Correspondence with European Commission regarding multiple applications. 6.17 List of Mock-ups or Samples/specimens sent with the application, as appropriate (see Notice to Applicants, volume 2A, chapter 7) 6.18 Copy of the Orphan Designation Decision. 6.19 List of proposed (invented) names and marketing authorisation holders in the concerned member states 6.20 Copy of EMEA certificate for a Vaccine Antigen Master File (VAMF) 6.21 Copy of EMEA certificate for a Plasma Master File (PMF) 6.22 For each active substance, attach a declaration from the Qualified Person of the manufacturing authorisation holder in Section 2.5.1 and from the Qualified Person of each of the manufacturing authorisation holders (i.e. located in EEA) listed in Section 2.5.2 where the active substance is used as a starting material that the active substance manufacturer(s) referred to in Section 2.5.3 operate in compliance with the detailed guidelines on good manufacturing practice for starting materials. This does not apply to Blood or blood components.

Module 1 New Requirements For each active substance, attach a declaration from the Qualified Person of the manufacturing authorisation holder in Section 2.5.1 and from the Qualified Person of each of the manufacturing authorisation holders (i.e. located in EEA) listed in Section 2.5.2 where the active substance is used as a starting material that the active substance manufacturer(s) referred to in Section 2.5.3 operate in compliance with the detailed guidelines on good manufacturing practice for starting materials. This does not apply to Blood or blood components.

Module 1 New Requirements Readability testing PIL Typical testing Participants (preferably patients) read the PIL Two rounds of interviews (10 in the first and 10-20 in the second round) Locate the information in the PIL Understand it Know how to act on it Might have to revise the PIL based on the outcome

Type of MA Application National Mutual Recognition Single member state (MS) Older well established products Mutual Recognition Approved in one MS, Reference Member State (RMS) Multiple identical MAs in many Concerned Member States (CMS) Harmonised MA granted Decentralised - New procedure! RMS and CMS Approved in all selected MS at the same time Centralised Mainly biotech products Single MA in all MS MA issued bye EMEA via the commission

Variations Maintaining the MAA Activities post approval Changing the way the product is made Additional manufacturing site Additional Drug Substance supplier– Dual sourcing policy Improve safety New indications Additional warnings Improve quality New stability results from commercial batches

Variations Maintaining the MAA New EU regulation regarding variations since Oct 2003 Type IA (minor) 14 days Type IB (minor) 30 days Type II (major) 60- 90 days Fundamental Variations (New application) Urgent safety restriction

Variations Maintaining the MAA Type IA (notification) “tell and do” Type IB (notification) “tell, wait and do” Type II (approval) “tell and wait” RMS is responsible for processing Type IA and IB on behalf of CMS

Variations Maintaining the MAA For each Type I variation, the guideline indicates; Details of the change Conditions/remarks attached to the change Documentation to be supplied 46 types of variations A variation is only regarded as Type I if the conditions are met AND the relevant supporting data are provided The variation will be considered Type II if either of these conditions are not met

Thank You!